Keywords
Canabidiol (CBD)
terapia complementar
How to Cite
Abstract
Introduction: Autism Spectrum Disorder (ASD) is characterized as a neurological condition with complex causes, potentially affecting social interactions and manifesting repetitive behaviors. Cannabidiol (CBD), a non-intoxicating component of the cannabis plant, shows therapeutic potential for relieving these symptoms safely and with minimal side effects, thereby improving the quality of life and daily functioning in individuals with ASD. Objective: This systematic review aims, through controlled studies, case reports, and reviews, to understand and describe the benefits and drawbacks of the relationship between individuals with ASD and the therapeutic use of CBD. Methodology: In this literature review, descriptors in Portuguese, English, and Spanish were used for bibliographic searches on databases such as Google Scholar, SciELO, PubMed, and BVS in September 2023. Inclusion criteria restricted articles to the last 5 years, published in Portuguese or English. Out of the initially identified 277 articles, 20 were selected. Results: The findings highlight improvements in social interaction, behavioral symptoms, and sleep quality with the use of CBD. However, there are reports of adverse effects such as drowsiness and decreased appetite, yet the majority of studies deem CBD to be safe. Conclusion: The research emphasizes the lack of a specific pharmacological treatment for ASD but underscores the importance of CBD as a complementary therapy, given the notable benefits and mild complications observed with the use of this substance. It further highlights the need for more medical and scientific research to better understand the effectiveness and potential adverse effects of CBD therapy in ASD.
References
ARAN, A. et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular Autism, v. 12, n. 1, 3 fev. 2021.
BURGGREN, A. C. et al. Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives. The American Journal of Drug and Alcohol Abuse, v. 45, n. 6, p. 1–17, 31 jul. 2019.
SCHNAPP, A. et al. A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ. Biomedicines, v. 10, n. 7, p. 1685, 13 jul. 2022.
STEFFEN, B. et al. Diagnóstico precoce de autismo: uma revisão literária. Revista saúde multidisciplinar, v. 6, n. 2, 2019.
PRETZSCH, C. M. et al. Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology, v. 44, n. 8, p. 1398–1405, 1 jul. 2019.
PRETZSCH, C. M. et al. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). Journal of Psychopharmacology, v. 33, n. 9, p. 1141–1148, 25 jun. 2019.
EFRON, D.; TAYLOR, K. Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders. International Journal of Environmental Research and Public Health, v. 20, n. 8, p. 5430, 7 abr. 2023.
SILVA, E. A. DA et al. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind and controlled placebo clinical trial. Trends in Psychiatry and Psychotherapy, v. 44, 26 maio 2022.
ALVES, F.. A utilização medicinal do canabidiol como recurso terapêutico: revisão bibliográfica. Revista Interfaces: Saúde, Humanas e Tecnologia, v. 8, n. 2, p. 581-590, 2020.
MINELLA, F.; LINARTEVICHI, V. Efeitos do canabidiol nos sinais e comorbidades do transtorno do espectro autista. Research, Society and Development, v. 10, n. 10, p. e64101018607-e64101018607, 2021.
PONTON, J. A. et al. A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report. Journal of Medical Case Reports, v. 14, n. 1, 22 set. 2020.
STABEN, J. et al. Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder. Frontiers in Neuroscience, v. 17, p. 1185737, 2023.
BEZERRA, L.; DA SILVA, N.; DE SOUZA, P. Medicamento derivado da maconha: Canabidiol e seus efeitos no tratamento de doenças do sistema nervoso. Brazilian Journal of Development, v. 6, n. 12, p. 94755-94765, 2020.
FUSAR-POLI, L. et al. Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. Brain Sciences, v. 10, n. 9, p. 572, 20 ago. 2020.
LIMA, L. et al. Avaliação dos benefícios do uso de canabidiol no tratamento de indivíduos com Transtorno do Espectro Autista (TEA). Brazilian Journal of Health Review, v. 6, n. 4, p. 17665-17680, 2023.
MA, L.; PLATNICK, S.; PLATNICK, H. Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study. Cureus, 26 ago. 2022.
DOS SANTOS SILVA, L. et al. Uso do canabidiol em crianças e adolescentes com transtorno do espectro autista no brasil: revisão de literatura. Revista Brasileira Interdisciplinar de Saúde, 2023.
DO CARMO CUPERTINO, M. et al. Transtorno do espectro autista: uma revisão sistemática sobre aspectos nutricionais e eixo intestino-cérebro. ABCS Health Sciences, v. 44, n. 2, 2019.
SIANI-ROSE, M. et al. Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder. Cannabis and Cannabinoid Research, v. 8, n. 1, p. 126-137, 2023.
PEREIRA, N.; BENTO, T. CANABIDIOL EM AUTISMO (TEA). ETIC-ENCONTRO DE INICIAÇÃO CIENTÍFICA-ISSN 21-76-8498, v. 19, n. 19, 2023.
RAZ, N. et al. Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report. Frontiers in Pharmacology, v. 13, 28 out. 2022.
Organização Mundial de Saúde (OMS). Autism spectrum disorders.
Disponível em: http://www.who.int/mediacentre/factsheets/autism-spectrum-disorders/en/. Acesso em: 2 jan. 2018.
STOLAR, O. et al. Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety. Frontiers in Pharmacology, v. 13, 29 set. 2022.
RUBENS P.; MOROTOMI, C.; PINTO, P. Unexpected improvement of hyperhidrosis with cannabidiol. Einstein (São Paulo), v. 20, 1 jan. 2022.
TERTULIANO, P.; PEREIRA, I.; SOBRINHO, H. O uso de canabidiol como terapia complementar no transtorno do espectro autista. Revista Brasileira Militar De Ciências, v. 7, n. 18, 2021.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Paloma Lara Ferreira Silva, Natália de Fátima Gonçalves Amâncio, Vanessa Pereira Tolentino